.24
  Price4.04%   -0.0101
(After Hours: .24 +0.0045 +1.87%)
Aug-11-22 09:15AM Rapt Therapeutics (RAPT) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research
Aug-08-22 05:25AM Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research
10:00AM Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out forZacks Investment Research
Aug-02-22 08:45AM Repligen (RGEN) Tops Q2 Earnings and Revenue EstimatesZacks Investment Research
Jul-22-22 05:04AM This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From YesterdayBenzinga
Jul-21-22 12:33PM Why Is Super Micro Computer Higher By More Than 13%? 42 Stocks Moving In Thursday's Mid-Day SessionBenzinga
11:49AM Vascular Biogenics (VBLT) Down, Ovarian Cancer Study FailsZacks Investment Research
Jul-21-22 10:06AM Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2022Benzinga
04:40AM Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From YesterdayBenzinga
Jul-20-22 02:36AM Gold Prices Settle Lower; Vascular Biogenics Shares PlummetBenzinga
12:50PM This Communication Services Stock Is Trading Higher By Over 82%, Here Are 45 Stocks Moving In Wednesday's Mid-Day SessionBenzinga
Jul-20-22 12:01PM Tech Shares Move Higher, Nasdaq Jumps 200 PointsBenzinga
10:21AM Why U.S. Stocks Are Trading Mixed; Existing Home Sales Tumble In JuneBenzinga
Jul-20-22 10:10AM Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022Benzinga
05:43AM Netflix And 15 Stocks Moving PremarketBenzinga
Jul-19-22 04:01AM VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian CancerGlobeNewswire Inc.
May-31-22 08:00AM VBL Therapeutics to Participate in the Jefferies Healthcare ConferenceGlobeNewswire Inc.
May-17-22 08:15AM Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research
May-16-22 08:15AM Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research
May-12-22 05:45AM ITeos Therapeutics, Inc. (ITOS) Surpasses Q1 Earnings and Revenue EstimatesZacks Investment Research
May-04-22 07:55AM Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research
Apr-28-22 10:09AM Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022Benzinga
Apr-26-22 09:30AM Hot Penny Stocks to Buy Today? 3 For Your Watchlist PennyStocks
09:04AM The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene TherapyBenzinga
Apr-01-22 08:36AM Fulcrum Therapeutics, Inc. (FULC) Stock Jumps 5.7%: Will It Continue to Soar?Zacks Investment Research
Mar-14-22 09:57AM UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23GlobeNewswire Inc.
08:00AM VLB Therapeutics to Report Year-End 2021 Financial Results on March 23GlobeNewswire Inc.
Feb-15-22 04:05AM VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.
Cap:    |  Volume (24h):